Based on a combined total of 234 patients with HER2-positive breast cancer who received at least one dose of T-DXd at 5.4 mg/kg in trials DESTINY-Breast01 (184 participants) and DS8201-A-J101 (50 participants), the safety assessment for T-DXd was conducted. Here, ERBB2 is linked to breast carcinoma.